188 related articles for article (PubMed ID: 23441215)
1. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.
Triulzi T; Casalini P; Sandri M; Ratti M; Carcangiu ML; Colombo MP; Balsari A; Ménard S; Orlandi R; Tagliabue E
PLoS One; 2013; 8(2):e56761. PubMed ID: 23441215
[TBL] [Abstract][Full Text] [Related]
2. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
3. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
4. A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
Lecchi M; Verderio P; Cappelletti V; De Santis F; Paolini B; Monica M; Sangaletti S; Pupa SM; Iorio MV; Bianchi G; Gennaro M; Fucà G; De Braud F; Tagliabue E; Di Nicola M
Mol Oncol; 2021 May; 15(5):1345-1357. PubMed ID: 33523584
[TBL] [Abstract][Full Text] [Related]
5. Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.
Rybinska I; Sandri M; Bianchi F; Orlandi R; De Cecco L; Gasparini P; Campiglio M; Paolini B; Sfondrini L; Tagliabue E; Triulzi T
Cells; 2020 Feb; 9(2):. PubMed ID: 32069815
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
[TBL] [Abstract][Full Text] [Related]
7. Prognostic stromal gene signatures in breast cancer.
Winslow S; Leandersson K; Edsjö A; Larsson C
Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.
Sangaletti S; Tripodo C; Santangelo A; Castioni N; Portararo P; Gulino A; Botti L; Parenza M; Cappetti B; Orlandi R; Tagliabue E; Chiodoni C; Colombo MP
Cell Rep; 2016 Sep; 17(1):233-248. PubMed ID: 27681434
[TBL] [Abstract][Full Text] [Related]
9. The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer.
Winslow S; Lindquist KE; Edsjö A; Larsson C
BMC Cancer; 2016 Nov; 16(1):841. PubMed ID: 27809802
[TBL] [Abstract][Full Text] [Related]
10. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
[TBL] [Abstract][Full Text] [Related]
11. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
Bergamaschi A; Tagliabue E; Sørlie T; Naume B; Triulzi T; Orlandi R; Russnes HG; Nesland JM; Tammi R; Auvinen P; Kosma VM; Ménard S; Børresen-Dale AL
J Pathol; 2008 Feb; 214(3):357-67. PubMed ID: 18044827
[TBL] [Abstract][Full Text] [Related]
12. Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer.
Tiwari S; Triulzi T; Holton S; Regondi V; Paolini B; Tagliabue E; Bhargava R
Sci Rep; 2020 Mar; 10(1):5442. PubMed ID: 32214177
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of the tumor microenvironment during breast cancer progression.
Ma XJ; Dahiya S; Richardson E; Erlander M; Sgroi DC
Breast Cancer Res; 2009; 11(1):R7. PubMed ID: 19187537
[TBL] [Abstract][Full Text] [Related]
14. In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome.
Myhre S; Mohammed H; Tramm T; Alsner J; Finak G; Park M; Overgaard J; Børresen-Dale AL; Frigessi A; Sørlie T
PLoS One; 2010 Nov; 5(11):e14002. PubMed ID: 21124964
[TBL] [Abstract][Full Text] [Related]
15. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.
Sakurai M; Miki Y; Takagi K; Suzuki T; Ishida T; Ohuchi N; Sasano H
Breast Cancer Res; 2017 Jun; 19(1):70. PubMed ID: 28629450
[TBL] [Abstract][Full Text] [Related]
16. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations.
Niemiec J; Adamczyk A; Małecki K; Ambicka A; Ryś J
Clin Breast Cancer; 2013 Apr; 13(2):119-28. PubMed ID: 23375518
[TBL] [Abstract][Full Text] [Related]
17. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
Front Immunol; 2020; 11():560074. PubMed ID: 33304345
[TBL] [Abstract][Full Text] [Related]
18. Stromal responses among common carcinomas correlated with clinicopathologic features.
Chen JL; Espinosa I; Lin AY; Liao OY; van de Rijn M; West RB
Clin Cancer Res; 2013 Sep; 19(18):5127-35. PubMed ID: 23804424
[TBL] [Abstract][Full Text] [Related]
19. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
Acs G; Esposito NN; Kiluk J; Loftus L; Laronga C
Mod Pathol; 2012 Apr; 25(4):556-66. PubMed ID: 22173289
[TBL] [Abstract][Full Text] [Related]
20. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
